These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28105975)

  • 1. Simultaneous Determination of First-Line 4-FDC Antituberculosis Drugs by UHPLC-UV and HPLC-UV: A Comparative Study.
    Franco PH; Chellini PR; Oliveira MA; Pianetti GA
    J AOAC Int; 2017 Jan; ():. PubMed ID: 28105975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Determination of First-Line 4-FDC Antituberculosis Drugs by UHPLC-UV and HPLC-UV: A Comparative Study.
    Franco PHC; Chellini PR; Oliveira MAL; Pianetti GA
    J AOAC Int; 2017 Jul; 100(4):1008-1015. PubMed ID: 28720173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of an HPLC Method for Simultaneous Determination of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol Hydrochloride in Pharmaceutical Formulations.
    Chellini PR; Lages EB; Franco PH; Nogueira FH; César IC; Pianetti GA
    J AOAC Int; 2015; 98(5):1234-9. PubMed ID: 26525241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
    Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
    Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of a reversed-phase-high-performance thin-layer chromatography method for the separation of isoniazid, ethambutol, rifampicin and pyrazinamide in fixed-dose combination antituberculosis tablets.
    Shewiyo DH; Kaale E; Risha PG; Dejaegher B; Smeyers-Verbeke J; Vander Heyden Y
    J Chromatogr A; 2012 Oct; 1260():232-8. PubMed ID: 22981506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice.
    Lai JML; Yang SL; Avoi R
    J Glob Infect Dis; 2019; 11(1):2-6. PubMed ID: 30814828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R; Sancheti P; Rungta S; Agrawal S; Kaul CL
    Pharmacol Res; 2003 Oct; 48(4):383-7. PubMed ID: 12902209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tackling quantitative polymorphic analysis through fixed-dose combination tablets production. Pyrazinamide polymorphic assessment.
    Antonio M; Raffaghelli M; Maggio RM
    J Pharm Biomed Anal; 2021 Feb; 194():113786. PubMed ID: 33281002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs.
    Bhutani H; Singh S; Jindal KC; Chakraborti AK
    J Pharm Biomed Anal; 2005 Oct; 39(5):892-9. PubMed ID: 15978767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparative Study of Newly Developed HPLC-DAD and UHPLC-UV Assays for the Determination of Posaconazole in Bulk Powder and Suspension Dosage Form.
    Hamdy DA; Belal TS
    J Anal Methods Chem; 2014; 2014():241035. PubMed ID: 25258695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous Quantitation of Amlodipine Besylate and Olmesartan Medoxomil in Fixed-Dose Combination Tablets: HPLC-DAD Versus UHPLC-DAD.
    Almeida MO; Fernandes C; Pianetti GA; César IC
    J Chromatogr Sci; 2018 Apr; 56(4):344-350. PubMed ID: 29409036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry.
    Song SH; Jun SH; Park KU; Yoon Y; Lee JH; Kim JQ; Song J
    Rapid Commun Mass Spectrom; 2007; 21(7):1331-8. PubMed ID: 17340570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS/MS: Application to therapeutic drug monitoring.
    Gao S; Wang Z; Xie X; You C; Yang Y; Xi Y; Chen W
    Tuberculosis (Edinb); 2018 Mar; 109():28-34. PubMed ID: 29559118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin.
    Mohan B; Sharda N; Singh S
    J Pharm Biomed Anal; 2003 Mar; 31(3):607-12. PubMed ID: 12615251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a HPLC Method for Analysis of a Combination of Clofazimine, Isoniazid, Pyrazinamide, and Rifampicin Incorporated into a Dermal Self-Double-Emulsifying Drug Delivery System.
    Staden DV; Haynes RK; Van der Kooy F; Viljoen JM
    Methods Protoc; 2023 Nov; 6(6):. PubMed ID: 37987351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.